Differences in Restenosis Rate With Different Drug-Eluting Stents in Patients With and Without Diabetes Mellitus
Authors:
- Ole FröbertOFOle Fröbert
- Bo LagerqvistBLBo Lagerqvist
- Jörg CarlssonJCJörg Carlsson
- Johan LindbäckJLJohan Lindbäck
- Ulf StenestrandUSUlf Stenestrand
- Stefan K. JamesSJStefan K. James
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary LesionsCirculation, 2008
- Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patientsEuropean Heart Journal, 2008
- Paclitaxel-Eluting Coronary Stents in Patients With Diabetes MellitusJACC, 2008
- Head-to-Head Comparison of Sirolimus- and Paclitaxel-Eluting Stent in the Same Diabetic Patient With Multiple Coronary Artery LesionsDiabetes Care, 2008
- Four-Year Clinical Follow-Up After Implantation of the Endeavor Zotarolimus-Eluting Stent: ENDEAVOR I, the First-in-Human StudyThe American Journal of Cardiology, 2007
- Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in the Treatment of Coronary Artery Disease in Patients With Diabetes MellitusThe American Journal of Cardiology, 2006
- Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic PatientsCirculation, 2005
- Paclitaxel-Eluting or Sirolimus-Eluting Stents to Prevent Restenosis in Diabetic PatientsNew England Journal of Medicine, 2005
- Predictors of Clinical Outcome Following NIR Stent Implantation for Coronary Artery Disease: Analysis of the Results of the First International New Intravascular Rigid‐Flex Endovascular Stent Study (FINESS Trial)Journal of Interventional Cardiology, 2002
- Diabetes mellitus and the clinical and angiographic outcome after coronary stent placementJACC, 1998